Trade LeMaitre Vascular Inc - LMAT CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.27
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021485 %(-$4.30)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02149%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000738 %(-$0.15)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021485 %
  (-$4.30)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000738 %
  (-$0.15)

Key Stats

• Prev. Close: 82.03
• Open: 81.46
• 1-Year Change: -15.06%
• Day's Range: 81.08 - 82.43

Trade LeMaitre Vascular Inc - LMAT

About LeMaitre Vascular Inc

LeMaitre Vascular, Inc. is a medical device company. The Company provides medical devices and human tissue cryopreservation services used in the treatment of peripheral vascular disease, end-stage renal disease and cardiovascular disease. It develops, manufactures and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons and neurosurgeons. Its portfolio of devices consists of products that are used in arteries and veins outside of the heart, which includes the LeMaitre valvulotome, the XenoSure biologic patch, the Artegraft collagen vascular graft, the Pruitt F3 carotid shunt, VascuTape radiopaque tape and Syntel embolectomy catheters. Its product line includes Valvulotomes, Surgical Glue, Remote Endarterectomy Devices, Radiopaque Tape, Powered Phlebectomy, ePTFE Vascular Grafts, Polyester Vascular Grafts, Ovine Vascular Grafts, Closure Systems, Carotid Shunts, Allografts, Angioscopes and many others.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, LeMaitre Vascular Inc revenues increased 19% to $154.4M. Net income increased 27% to $26.9M. Revenues reflect United States segment increase of 25% to $93.9M, Other countries segment increase of 14% to $47.6M. Net income benefited from Foreign currency loss decrease of 65% to $116K (expense). Dividend per share increased from $0.37 to $0.43.

Equity composition

Common Stock $.01 Par, 03/11, 100M auth., 16,144,485 issd., less 639,155 shs. in Treas. @ $3.8M. Insiders control 36.71%. IPO: 10/06,5.5M shs. @ $7 per share by Goldman, Sachs & Co., CIBC Worlds Markets, Cowen & Co. and Thomas Weisel Partners LLC. Pref. Stock $.01 Par, 5M auth.,none issued.